COVID-19 and renin-angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) - Is there any scientific evidence for controversy?

A. Aleksova, F. Ferro, G. Gagno, C. Cappelletto, D. Santon, M. Rossi, G. Ippolito, A. Zumla, A. P. Beltrami, G. Sinagra

Research output: Contribution to journalReview article

Abstract

Renin–angiotensin system (RAS) blockers are extensively used worldwide to treat many cardiovascular disorders, where they are effective in reducing both mortality and morbidity. These drugs are known to induce an increased expression of angiotensin-converting enzyme 2 (ACE2). ACE2 acts as receptor for the novel SARS coronavirus-2 (SARS-CoV-2) which raising the important issue of possible detrimental effects that RAS blockers could exert on the natural history and pathogenesis of the coronavirus disease-19 (COVID-19) and associated excessive inflammation, myocarditis and cardiac arrhythmias. We review the current knowledge on the interaction between SARS-CoV-2 infection and RAS blockers and suggest a scientific rationale for continuing RAS blockers therapy in patients with COVID-19 infection.

Original languageEnglish
Pages (from-to)1-25
Number of pages25
JournalJournal of Internal Medicine
DOIs
Publication statusE-pub ahead of print - May 27 2020

Keywords

  • ACEIs/ARBs
  • angiotensin-converting enzyme 2 (ACE2)
  • cardiovascular system
  • COVID-19
  • pandemic
  • RAAS
  • SARS coronavirus (CoV)-2

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'COVID-19 and renin-angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) - Is there any scientific evidence for controversy?'. Together they form a unique fingerprint.

  • Cite this